Open in interactive viewer → charts, metric popovers & call review

Imperial Brands' Seventh Year: A Missing Zero, a Retired KPI, and Another Second-Half Bet

FY26 landed exactly on guidance — which is why the interesting details were the cost target that quietly grew and the share metric management stopped leaning on.
IMB.L · Earnings Call · 2026-11-17

A Clean Print — Which Is Not the Story

Imperial Brands' FY26 was, by the numbers, precisely what the sell side had been told to expect. Tobacco & NGP net revenue rose 2.1%, group adjusted operating profit 3.7% (inside the 3-5% target range), adjusted EPS 8.8%, free cash flow £2.6bn, and leverage closed at 2.0x — the bottom of the 2.0-2.5x range — funding a 4% dividend increase and an evergreen buyback lifted to £1.5bn for FY27 from £1.45bn. Lukas Paravicini, a year into the chief executive role, called it the sixth consecutive year of growth in both revenue and profit and organised the entire morning around the value creation model he unveiled at last year's Capital Markets Day: revenue growth, operational gearing, transformation savings, and a buyback that converts profit growth into faster EPS growth. Underneath the dashboard, three things actually moved — and none of them are in the headline.

The Target That Grew a Zero

At the CMD the cost-savings programme was sized at £320m. On Tuesday, Lukas referred in passing to "our pathway to delivering annualized savings of at least GBP 300 million by 2030." An analyst picked at the gap. Murray McGowan's answer was the most candid twenty seconds of the call:

So on the cost savings, yes, I think we targeted GBP 320 million. We're now saying at least GBP 320 million. You are being pedantic, we notice the difference.

Murray McGowan, Chief Financial Officer · 2026-11-17
To be fair to them, the delivery is real and materially ahead of what was said six months ago. Year one has banked £90m of annualized savings, and actions already taken will underpin a further £90m — "well over half" the target with four years still to run. Contrast that with the May 2026 call, when the framing was £25m from factory efficiency this year and £100m arriving "progressively" from exiting two entities. That is a genuine step-up in both the claim and the confidence behind it. But the 300-vs-320 slip is a small tell about how targets get surfaced at Imperial: the number that anchors the strategy slides and the number that anchors the cash guidance are not always the same number, and it takes an analyst's pedantry to force the reconciliation into the open.

What Management Stopped Saying

For five years Imperial's equity story rested on one sentence: we are no longer the industry's biggest share donor, and our goal is stable aggregate share in the top five markets. In November 2025, Lukas put it as plainly as it can be put: “The goal is stable market share. That's what is in our model.” — Lukas Paravicini, CEO · 2025-11-18 On Tuesday, the aggregate number was retired. “Over time, the high-level 5 market aggregate share figure has become less aligned to how we manage the business.” — Lukas Paravicini, Chief Executive Officer · 2026-11-17 In its place: brand market combination tracking — 27 distinct brand-by-market cells across three regions, each managed on its own price/volume/mix trade-off. Share "remains very important," Lukas stressed, but the way to read Imperial is now segment by segment, brand by brand. This is a sensible operating philosophy and also a convenient one. When the single number you have spent five years promising to stabilise starts getting harder to hold — the U.S. ceded 15 basis points of a 174-basis-point six-year gain, Germany is "almost flattish" — the defensible move is to stop publishing the aggregate and start publishing the cells. Watch whether the 27 cells ever get reported with the same discipline the five markets did. The U.S. detail, at least, was good: 8.1% pricing against 4.8% volume decline for 3.3% tobacco net revenue growth.

Duty Drawback: Tobacco's Longest-Running 'Next Year' Story

Duty drawback has now been a top-ranked Imperial keyword for four consecutive quarters. It has also been scheduled identically for four consecutive quarters. In November 2025: “it's less a question of if, it's more a question of when.” — Lukas Paravicini, CEO · 2025-11-18 In May 2026: “most likely towards the second half of -- excuse me... '27. ... and then the full impact in fiscal year '28.” — Lukas Paravicini, Chief Executive Officer · 2026-05-12 On Tuesday, same schedule, slightly firmer language: “the full effect you will see in '28. But it is quite a swift ramp-up in the second half.” — Lukas Paravicini, Chief Executive Officer · 2026-11-17 Nothing changed. That is the finding. Two years of analyst airtime, one identical answer — and FY27 guidance now leans on it as one of three named drivers of a heavily back-weighted year.

The Second-Half Bet

FY27 guidance: low single-digit tobacco revenue growth, double-digit NGP revenue growth, adjusted operating profit "a similar level to FY26" inside 3-5%, at least high single-digit EPS, free cash flow of at least £2.2bn (down from £2.6bn), interest costs around £500m and a tax rate of 24.5-25% versus 23.4%. Phasing is "more weighted to the second half than in FY '26," driven by front-loaded modern oral investment behind Black Buffalo and Helwit, a Ukraine supply-chain restock, and the drawback landing in H2. Asked directly whether first-half operating profit could be negative, Murray did not deny it: “we don't guide on operating profit at the half year. We just want to give you a sense of the phasing.” — Murray McGowan, Chief Financial Officer · 2026-11-17 Meanwhile £2.8bn of FY26 dividends and buybacks exceeded £2.6bn of free cash flow, a gap the CFO effectively confirmed is deliberate: “That means that we can potentially pay out more the free cash flow in terms of our dividend plus our capital allocation.” — Murray McGowan, Chief Financial Officer · 2026-11-17 Leverage at the low end is the buffer. For a company that spent 2021-2022 telling investors it could not return capital until it hit 2x, paying above free cash flow while free cash flow itself steps down is a notable evolution.

The One Genuine Macro Confluence

Most of Imperial's headwinds are idiosyncratic — the excise tax front-loading in Germany (up to £20m of FY27 profit impact), the Australian legal-market contraction, the warehouse attack in Ukraine. But two are market-wide. The £500m interest bill is a refinancing story: bonds issued in a much lower-rate world are maturing into today's curve, exactly the Rising interest rate environments pressure showing up across the global keyword set, and the guidance line here is explicit about upward pressure on interest. The second is the new reporting segment. From FY27 Imperial will disclose a smokeless category combining NGP with the Nordic oral nicotine business — £554m of FY26 net revenue and, crucially, £14m of positive adjusted operating profit. That reframes a decade-long NGP loss narrative into a profitable reduced-risk franchise, and it invites direct comparison with peers who already report that way. It also quietly marks a pivot: in May, Lukas was dismissive of pouches — “The data is showing that the markets are very small” — Lukas Paravicini, Chief Executive Officer · 2026-05-12 — and by Tuesday Black Buffalo was being described as "an opportunity to create a more material modern oral business in the U.S."

Bottom Line

The print is clean and the model is working. But the tells are in the edges: a savings target that gained a zero under questioning, a flagship share metric retired at precisely the moment it became harder to hold, a drawback benefit still two years from full effect, and a year shaped so that almost all of the growth arrives after March. Imperial has earned the benefit of the doubt on delivery. It has not yet earned it on the aggregate share number it no longer wants to show.